Objective: For patients with recurrent/metastatic head and neck squamous cell carcinoma (R/MHNSCC), platinum-free interval (PFI)-based differences in the effectiveness of rechallenge with platinum-based chemotherapy (PBCT) remain unknown. We aimed to evaluate the difference in platinum sensitivity based on PFI in R/MHNSCC.
Methods: We retrospectively examined 80 patients with R/MHNSCC who underwent PBCT between 2001 and 2020. Treatment efficacy was compared between patients with prior PBCT for treatment of recurrence/metastasis or concurrent chemoradiotherapy during radical treatment (rechallenge group) and those without (control group). Patients with prior PBCT (rechallenge group) were stratified by PFI. PFI was defined as the period from the last dosing date with the previous platinum agent to rechallenge with PBCT.
Results: Of 80 patients, 55 had been with prior PBCT (rechallenge group) and 25 had been without prior PBCT (control group). The rechallenge group was divided into three groups: PFI <6 months (10), PFI 6-11 months (17), and PFI ≥12 months (28). The PFI <6-month group had shorter overall survival (p=0.047, the log-rank test) and lower disease control rate (p=0.02, Fisher's exact test) than the control group. The PFI 6-11- and ≥12-month group outcomes did not significantly differ from those of the control group.
Conclusions: Patients with PFI <6 months tend to have a poorer prognosis after rechallenge with PBCT than patients without prior PBCT, suggesting that PFI 6 months may be considered as a threshold of platinum resistance and rechallenge with PBCT may be a valid option in PFI ≥6 months.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.anl.2023.05.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Urothelial Cancer.
Clin Genitourin Cancer
October 2023
Division of Medical Oncology, AO Ordine Mauriziano Hospital, Turin, Italy.
Article Synopsis
- PARP inhibitors (PARPis) show potential therapeutic benefits in urothelial cancer (UC), especially due to high rates of homologous-recombination repair deficiency and possible cross-sensitivity with platinum-based chemotherapy.
- Several trials have been conducted, particularly focusing on maintenance therapy and the combination with immune-checkpoint inhibitors (ICIs), although results have been mixed, with some showing improved outcomes in specific groups and others proving ineffective.
- Identifying patients with HRR aberrations is crucial for maximizing the effectiveness of PARPis, as current evidence indicates that their best applications may be in maintenance settings or in conjunction with ICIs for platinum-naïve patients.
Platinum resistance and sensitivity in recurrent/metastatic head and neck squamous cell carcinoma.
Auris Nasus Larynx
February 2024
Department of Head and Neck Surgery, Hyogo Cancer Center, 13-70 Kitaohji, Akashi, Hyogo 673-8558, Japan.
Objective: For patients with recurrent/metastatic head and neck squamous cell carcinoma (R/MHNSCC), platinum-free interval (PFI)-based differences in the effectiveness of rechallenge with platinum-based chemotherapy (PBCT) remain unknown. We aimed to evaluate the difference in platinum sensitivity based on PFI in R/MHNSCC.
Methods: We retrospectively examined 80 patients with R/MHNSCC who underwent PBCT between 2001 and 2020.
Mortality and Second Cancer Incidence After Treatment for Testicular Cancer: Psychosocial Health and Lifestyle Are Modifiable Prognostic Factors.
J Clin Oncol
August 2022
Department of Research and Innovation, Møre and Romsdal Hospital Trust, Ålesund, Norway.
Purpose: To evaluate whether selected modifiable patient-reported adverse health outcomes (AHOs) in testicular cancer survivors (TCSs) represent prognostic factors of overall mortality, cancer mortality, and first-time non-germ cell second cancer (SecCa) incidence.
Patients And Methods: In 775 long-term TCSs (diagnosis: 1980-1994) who previously participated in a quality-of-life survey, 20-year mortality and SecCa incidence were compared between the surgery group (n = 272) and TCSs after platinum-based chemotherapy (PBCT; n = 503). A PBCT standard group (total cisplatin: ≤ 630 mg: n = 124) was separated from a PBCT high subgroup (total cisplatin: > 630 mg; n = 379).
Maintenance chemotherapy is effective in patients with metastatic triple negative breast cancer after first-line platinum-based chemotherapy.
Ann Palliat Med
September 2020
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Article Synopsis
- Platinum-based chemotherapy (PBCT) is an effective first-line treatment for metastatic triple-negative breast cancer (mTNBC), and this study explored whether continuing maintenance chemotherapy is better than just monitoring patients after initial treatment.
- Among 265 mTNBC patients, those who received maintenance therapy had a statistically significant longer median progression-free survival (PFS) of 9.63 months compared to 7.47 months for those who were only observed, along with improved overall survival (OS) rates.
- The findings suggest that maintenance chemotherapy offers a survival advantage for patients not showing disease progression after initial PBCT treatment, although it can lead to some adverse events like hematologic toxicity and hand-foot syndrome.
Three-dimensional visualization of microvasculature from few-projection data using a novel CT reconstruction algorithm for propagation-based X-ray phase-contrast imaging.
Biomed Opt Express
January 2020
School of Biomedical Engineering and Technology, Tianjin Medical University, Tianjin 300070, China.
Propagation-based X-ray phase-contrast imaging (PBI) is a powerful nondestructive imaging technique that can reveal the internal detailed structures in weakly absorbing samples. Extending PBI to CT (PBCT) enables high-resolution and high-contrast 3D visualization of microvasculature, which can be used for the understanding, diagnosis and therapy of diseases involving vasculopathy, such as cardiovascular disease, stroke and tumor. However, the long scan time for PBCT impedes its wider use in biomedical and preclinical microvascular studies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!